Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeTe: Metronomic Temozolomide in Unfit Patients with Advanced Neuroendocrine Neoplasms
2020-005393-10Phase 2Active
- Sponsor
- European Institute of Oncology
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in Well-differentiated neuroendocrine neoplasm (WD-NEN) and neuroendocrine carcinoma (NEC), sponsored by European Institute of Oncology. Primary endpoint: Progression-free survival. Started Aug 2021; status: active.
02
Drugs
temozolomide
03
Conditions
Well-differentiated neuroendocrine neoplasm (WD-NEN)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2020-005393-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005393-10.